Little Rock, AR – InterveXion Therapeutics has received a federal grant to fund a second clinical study of IXT-m200, a monoclonal antibody designed to treat methamphetamine abuse. The clinical trial, called STAMPOUT, will be a Phase 2a, parallel-group,...read more
Little Rock, AR - Following the successful completion of Phase 1 clinical safety evaluation for the novel anti-methamphetamine antibody IXT-m200 (ch-mAb7F9), InterveXion has announced plans to continue clinical development of this agent. The STAMPOUT study will be a...read more
InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction
Little Rock, AR – InterveXion Therapeutics, a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IXT-m200, also known as ch-mAb7F9, an investigational drug candidate for the...read more
InterveXion Therapeutics (Little Rock, AR) is a pharmaceutical company whose mission is to discover and advance innovative medications that reduce the impact of human suffering on individuals and communities. Our vision is to be a leader in the development of antagonist therapies that neutralize toxins in the body and thereby improve patient health. InterveXion’s first medications are a monoclonal antibody (mAb) and an active vaccine for treating methamphetamine (METH) abuse.